ClinicalTrials.gg
CompletedNCT00264550GO-FORWARDUpdated Apr 29, 2014Results posted

An Efficacy and Safety Study of Golimumab in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy

A Phase 3 interventional study of Golimumab 100 mg and Golimumab 50 mg in Rheumatoid Arthritis, sponsored by Centocor, Inc.. Completed at 52 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-04-29.

Sponsored by Centocor, Inc. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
444
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 16 studies testing golimumab in Arthritis, Rheumatoid — 2 open to participants now, 2 under way, 1 of them phase 3. golimumab · Arthritis, Rheumatoid.

Enrollment
6th of 16
444 · median 356
Started
2005
with 1 other
Phase 3
11 of 16
1 open now
Registered
2nd of 16
by date
Lead sponsor
8 of 16
Centocor, Inc.

Among the 16 studies testing golimumab in Arthritis, Rheumatoid, this one is the 6th largest by enrollment, is one of 2 that started in 2005, is one of 11 in phase 3, and was the 2nd registered.

Arthritis, Rheumatoid

3,336 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

2 of the 16 studies testing golimumab in Arthritis, Rheumatoid are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About golimumab

golimumab: first FDA approval 2009 (SIMPONI), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing golimumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of golimumab, alone or in combination with methotrexate (MTX), as compared to methotrexate alone in rheumatoid arthritis (RA) patients who have active rheumatoid arthritis despite treatment with MTX.

Read the detailed description

This is a randomized (treatment is assigned by chance), double-blind (neither the physician nor the patient is aware of the received treatment), placebo-controlled study of multiple subcutaneous (SC) administrations of golimumab at 2 doses as monotherapy or in combination with MTX in patients with active RA despite treatment with MTX. The duration of participation in the study for an individual patient will be upto 268 weeks. The patients will be randomly assigned in a 3:3:2:2 ratio to receive golimumab 50 mg or 100 mg or placebo injections under the skin every 4 weeks through week 20 and methotrexate or placebo capsules will be given in addition. At Week 24, all subjects will receive golimumab 50mg or 100mg injections, and golimumab continues for all groups for about 4 and a half more years. At Week 16 any patient in the study who meets criteria for \< 20% improvement from baseline in both swollen and tender joint count will enter early escape in a double-blinded fashion. Treatment during the long-term extension will start at Week 52 and continue every 4 weeks thereafter for a total of approximately 5 years from the initial (Week 0) administration of study agent. Patients will return for scheduled follow-up visits generally every 12 weeks for a total length of follow-up of approximately 5 years from the first administration of the study drug.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Rheumatoid Arthritis
  • Golimumab
  • Methotrexate
  • Fully Human anti-TNFa monoclonal antibody
  • Simpony
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of rheumatoid arthritis (RA) (according to the revised 1987 criteria of the ACR) for at least 3 months prior to screening
  • Must have been treated with and tolerated methotrexate (MTX) at a dose of at least 15 mg/week for at least 3 months prior to screening, and have a MTX dose of >=15 mg/week and \<=25 mg/week and stable for at least 4 weeks prior to screening
  • Have active RA as defined by persistent disease activity with at least 4 swollen and 4 tender joints, at the time of screening and baseline, and at least 2 of the following 4 criteria: a)C-reactive protein (CRP) >=1.5 mg/dL at screening or erythrocyte sedimentation rate (ESR) by Westergren method of >= 28 mm in the first hour at screening or baseline, b)Morning stiffness of >= 30 minutes at screening and baseline, c)Bone erosion by x-ray and/or magnetic resonance imaging (MRI) prior to first administration of study agent, d)Anti-cyclic citrullinated peptide (anti-CCP) antibody-positive or rheumatoid factor (RF) positive at screening
  • If using oral , must be on a stable dose equivalent to \<= 10 mg of prednisone/day for at least 2 weeks prior to first administration of study agent
  • Are considered eligible according to specified tuberculosis (TB) screening criteria

Exclusion criteria

Exclusion Criteria:

  • Have inflammatory diseases other than RA that might confound the evaluation of the benefit of golimumab therapy
  • Have had treatment with disease-modifying anti-rheumatic drugs (DMARDs)/systemic immunosuppressives other than MTX, during the 4 weeks prior to the first administration of study agent
  • Have had prior treatment with biologic anti-tumor necrosis factor (TNF) drugs (infliximab, etanercept, adalimumab)
  • Have had history of, or ongoing, chronic or recurrent infectious disease.
  • Have serious infection within 2 months prior to first administration of study agent
  • Have a history of latent or active granulomatous infection, including TB, histoplasmosis, or coccidioidomycosis, prior to screening
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
444 participants (actual)

Study arms

  • Placebo comparator
    Group 1: Placebo + Methotrexate

    Placebo subcutaneous (SC) injections every 4 weeks from Week 0 to Week 20 (early escape at Week 16); Methotrexate - 15 to 25mg weekly from Week 0 up to 5 yrs; Golimumab - if early escape, 50mg SC injections every 4 weeks from Week 16 up to 5 years; Golimumab - 50 mg SC injections every 4 weeks from Week 24 up to 5 yrs (unless early escape); Methotrexate - Dr's discretion, weekly dose adjusted after unblinding; Golimumab - Dr's discretion after unblinding, dose adjusted from 50 to 100mg and from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.

    Drug: Methotrexate · Drug: Placebo injection

  • Experimental
    Group 2: Golimumab 100 mg + Placebo

    Golimumab 100 mg SC injections every 4 weeks from Week 0 up to 5 yrs; Placebo - 7-10 capsules weekly during blinded period (or Week 16 if early escape); Methotrexate - if early escape, 15 to 25mg weekly from Week 16 up to 5 yrs; Methotrexate - Dr's discretion, weekly dose adjusted after unblinding; Golimumab - Dr's discretion after unblinding, dose adjusted from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.

    Drug: Golimumab 100 mg · Drug: Placebo capsules

  • Experimental
    Group 3: Golimumab 50 mg + Methotrexate

    Golimumab 50 mg SC injections every 4 weeks from Week 0 up to 5 yrs (unless early escape at Week 16); Methotrexate - 15 to 25 mg weekly from Week 0 up to 5 years; Golimumab - if early escape, 100 mg SC injections every 4 weeks from Week 16 up to 5 yrs; Methotrexate - Dr's discretion, weekly dose adjusted after unblinding; Golimumab - Dr's discretion after unblinding, dose adjusted from 50 to100mg and from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.

    Drug: Golimumab 50 mg · Drug: Methotrexate

  • Experimental
    Group 4: Golimumab 100 mg + Methotrexate

    Golimumab100 mg SC injections every 4 weeks from Week 0 up to 5 yrs; Methotrexate - 15 to 25 mg weekly from Week 0 up to 5 yrs; Methotrexate - Dr's discretion, weekly dose adjusted after unblinding; Golimumab - Dr's discretion after unblinding, dose adjusted from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.

    Drug: Golimumab 100 mg · Drug: Methotrexate

Interventions

  • Participants will receive subcutaneous (SC) injections of golimumab 100 mg every 4 weeks.

  • Participants will receive subcutaneous (SC) injections of golimumab 50 mg every 4 weeks.

  • Participants will receive methotrexate capsules weekly.

  • DrugPlacebo injection

    Participants will receive subcutaneous (SC) injections of placebo every 4 weeks.

  • DrugPlacebo capsules

    Participants will receive placebo capsules weekly

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Achieved American College of Rheumatology (ACR) 20 Response at Week 14

    ACR 20 response is defined as a greater than or equal to 20 percent improvement from baseline in: 1. Swollen joint count (66 joints) and tender joint count (68 joints) 2. greater than or equal to 50 percentage improvement in 3 of the following 5 assessments: a. Patient's assessment of pain of pain by the Visual Analogue Scale (VAS) (0-10 cm) b.Patient's Global Assessment of Disease activity VAS (0-10 cm) c. Physician's Global Assessment of Disease Activity VAS (0-10 cm) d. Patient's assessment of physical function as measured by the Health Assessment Questionnaire (HAQ) e. C reactive protein.

    Time frame: Week 14

  2. Change From Baseline in Health Assessment Questionnaire (HAQ) Score at Week 24

    HAQ is 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0 (no difficulty), to 3 (inability to perform a task in that area). The average score across the functional areas yields an overall HAQ score which ranges from 0 (no disability) to 3 (completely disabled).

    Time frame: Baseline (Week 0) and Week 24

Secondary outcomes

  1. Number of Participants With Disease Activity Index Score 28 (DAS 28) Using C-reactive Protein (CRP) Response at Week 14

    DAS 28 using CRP is an index to measure the disease activity in participants with rheumatoid arthritis which combines tender joint count (28 joints), swollen joint count (28 joints), CRP value, and participant's global assessment of disease activity (using a Visual Analog Scale of 0 to 100 mm). The DAS 28 score ranges from 0 (best) to 10 (worst). Participants are considered to have a DAS 28 response if they have a score of \<= 3.2 (good response) or \> 3.2 to 5.1 (moderate response).

    Time frame: Week 14

  2. Number of Participants Who Achieved American College of Rheumatology 20 (ACR 20) Response at Week 24

    An ACR 20 response is defined as a greater than or equal to 20 percent improvement from baseline in: 1. Swollen joint count (66 joints) and tender joint count (68 joints) 2. greater than or equal to 50 percentage improvement in 3 of the following 5 assessments: a. Patient's assessment of pain (VAS) (0-10 cm) b.Patient's Global Assessment of Disease activity (VAS) (0-10 cm) c. Physician's Global Assessment of Disease Activity (VAS) (0-10 cm) d. Patient's assessment of physical function as measured by the Health Assessment Questionnaire (HAQ) e. C reactive protein (CRP).

    Time frame: Week 24

  3. Change From Baseline in Health Assessment Questionnaire (HAQ) Score at Week 14

    The HAQ is 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0 (no difficulty), to 3 (inability to perform a task in that area). The average score across the functional areas yields an overall HAQ score which ranges from 0 (no disability) to 3 (completely disabled).

    Time frame: Baseline (Week 0) and Week 14

  4. Change From Baseline in Total Van Der Heijde Modified Sharp (vdH-S) Score at Week 24

    The vdH-S score is the sum of joint erosion score and joint-space narrowing (JSN) score. The total score ranges from 0 (best) to 448 (worst) with higher scores indicating more joint damage.

    Time frame: Baseline (Week 0) and Week 24

07

Results

Posted Mar 21, 2014
Limitations and caveats
The count of patients with any nonserious adverse events (NAE) excludes patients who only had NAE that occurred in \<= 5% of patients. This information may vary from existing approved labeling and publications due to the requirement of this website.

Participant flow

A total of 444 participants were enrolled at 60 sites in 12 countries.

Participant flow — Overall Study
MilestoneGroup 1: Placebo + MethotrexateGroup 2: Golimumab 100 mg + PlaceboGroup 3: Golimumab 50 mg + MethotrexateGroup 4: Golimumab 100 mg + Methotrexate
Started1331338989
Completed90927259
Not completed43411730
Withdrew: Death0300
Withdrew: Lost to follow-up3111
Withdrew: Adverse event2318914
Withdrew: Unsatisfactory therapeutic effect41146
Withdrew: Discontinued oral study agent0100
Withdrew: Other13739

Outcome measures

PrimaryNumber of Participants Who Achieved American College of Rheumatology (ACR) 20 Response at Week 14

ACR 20 response is defined as a greater than or equal to 20 percent improvement from baseline in: 1. Swollen joint count (66 joints) and tender joint count (68 joints) 2. greater than or equal to 50 percentage improvement in 3 of the following 5 assessments: a. Patient's assessment of pain of pain by the Visual Analogue Scale (VAS) (0-10 cm) b.Patient's Global Assessment of Disease activity VAS (0-10 cm) c. Physician's Global Assessment of Disease Activity VAS (0-10 cm) d. Patient's assessment of physical function as measured by the Health Assessment Questionnaire (HAQ) e. C reactive protein.

Time frame:
Week 14
Reported as:
Number · Participants
Number of Participants Who Achieved American College of Rheumatology (ACR) 20 Response at Week 14
ParticipantsGroup 1: Placebo + MethotrexateGroup 2: Golimumab 100 mg + PlaceboGroup 3: Golimumab 50 mg + MethotrexateGroup 4: Golimumab 100 mg + MethotrexateCombined Golimumab + Methotrexate
Number of Participants Who Achieved American College of Rheumatology (ACR) 20 Response at Week 144459495099
Statistical analysis
  • Group 1: Placebo + Methotrexate vs Combined Golimumab + Methotrexate · Chi-squared · p = <0.001 (The positive test is defined if the comparison between combined golimumab+MTX and Group 1 is significant at the 0.05, and at least one of the pair-wise comparisons is also significant at the 0.05.)
  • Group 1: Placebo + Methotrexate vs Group 3: Golimumab 50 mg + Methotrexate · Chi-squared · p = 0.001
  • Group 1: Placebo + Methotrexate vs Group 4: Golimumab 100 mg + Methotrexate · Chi-squared · p = <0.001
  • Group 1: Placebo + Methotrexate vs Group 2: Golimumab 100 mg + Placebo · Chi-squared · p = 0.059 (This null hypothesis is tested only if a positive test for null hypothesis Statistical Analysis 1.)
SecondaryNumber of Participants With Disease Activity Index Score 28 (DAS 28) Using C-reactive Protein (CRP) Response at Week 14

DAS 28 using CRP is an index to measure the disease activity in participants with rheumatoid arthritis which combines tender joint count (28 joints), swollen joint count (28 joints), CRP value, and participant's global assessment of disease activity (using a Visual Analog Scale of 0 to 100 mm). The DAS 28 score ranges from 0 (best) to 10 (worst). Participants are considered to have a DAS 28 response if they have a score of \<= 3.2 (good response) or \> 3.2 to 5.1 (moderate response).

Time frame:
Week 14
Reported as:
Number · Participants
Number of Participants With Disease Activity Index Score 28 (DAS 28) Using C-reactive Protein (CRP) Response at Week 14
ParticipantsGroup 1: Placebo + MethotrexateGroup 2: Golimumab 100 mg + PlaceboGroup 3: Golimumab 50 mg + MethotrexateGroup 4: Golimumab 100 mg + MethotrexateCombined Golimumab + Methotrexate
Number of Participants With Disease Activity Index Score 28 (DAS 28) Using C-reactive Protein (CRP) Response at Week 1467846467131
Statistical analysis
  • Group 1: Placebo + Methotrexate vs Combined Golimumab + Methotrexate · Chi-squared · p = <0.001
  • Group 1: Placebo + Methotrexate vs Group 3: Golimumab 50 mg + Methotrexate · Chi-squared · p = 0.001
  • Group 1: Placebo + Methotrexate vs Group 4: Golimumab 100 mg + Methotrexate · Chi-squared · p = <0.001
  • Group 1: Placebo + Methotrexate vs Group 2: Golimumab 100 mg + Placebo · Chi-squared · p = 0.035
PrimaryChange From Baseline in Health Assessment Questionnaire (HAQ) Score at Week 24

HAQ is 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0 (no difficulty), to 3 (inability to perform a task in that area). The average score across the functional areas yields an overall HAQ score which ranges from 0 (no disability) to 3 (completely disabled).

Time frame:
Baseline (Week 0) and Week 24
Reported as:
Median · Units on a scale
Change From Baseline in Health Assessment Questionnaire (HAQ) Score at Week 24
Units on a scaleGroup 1: Placebo + MethotrexateGroup 2: Golimumab 100 mg + PlaceboGroup 3: Golimumab 50 mg + MethotrexateGroup 4: Golimumab 100 mg + MethotrexateCombined Golimumab + Methotrexate
Change From Baseline in Health Assessment Questionnaire (HAQ) Score at Week 240.1250 (-0.1250 to 0.3750)0.1250 (-0.2500 to 0.6250)0.3750 (0.1250 to 0.7500)0.5000 (0.1250 to 0.7500)0.4375 (0.1250 to 0.7500)
Statistical analysis
  • Group 1: Placebo + Methotrexate vs Combined Golimumab + Methotrexate · ANOVA on van der Waerden normal scores. · p = <0.001 (The positive test is defined if the comparison between combined golimumab+MTX and Group I is significant at the 0.05, and at least one of the pair-wise comparisons is also significant at the 0.05.)
  • Group 1: Placebo + Methotrexate vs Group 3: Golimumab 50 mg + Methotrexate · ANOVA on van der Waerden normal scores. · p = <0.001
  • Group 1: Placebo + Methotrexate vs Group 4: Golimumab 100 mg + Methotrexate · ANOVA on van der Waerden normal scores. · p = <0.001
  • Group 1: Placebo + Methotrexate vs Group 2: Golimumab 100 mg + Placebo · ANOVA on van der Waerden normal scores. · p = 0.240
SecondaryNumber of Participants Who Achieved American College of Rheumatology 20 (ACR 20) Response at Week 24

An ACR 20 response is defined as a greater than or equal to 20 percent improvement from baseline in: 1. Swollen joint count (66 joints) and tender joint count (68 joints) 2. greater than or equal to 50 percentage improvement in 3 of the following 5 assessments: a. Patient's assessment of pain (VAS) (0-10 cm) b.Patient's Global Assessment of Disease activity (VAS) (0-10 cm) c. Physician's Global Assessment of Disease Activity (VAS) (0-10 cm) d. Patient's assessment of physical function as measured by the Health Assessment Questionnaire (HAQ) e. C reactive protein (CRP).

Time frame:
Week 24
Reported as:
Number · Participants
Number of Participants Who Achieved American College of Rheumatology 20 (ACR 20) Response at Week 24
ParticipantsGroup 1: Placebo + MethotrexateGroup 2: Golimumab 100 mg + PlaceboGroup 3: Golimumab 50 mg + MethotrexateGroup 4: Golimumab 100 mg + MethotrexateCombined Golimumab + Methotrexate
Number of Participants Who Achieved American College of Rheumatology 20 (ACR 20) Response at Week 2437475353106
Statistical analysis
  • Group 1: Placebo + Methotrexate vs Combined Golimumab + Methotrexate · Chi-squared · p = <0.001
  • Group 1: Placebo + Methotrexate vs Group 3: Golimumab 50 mg + Methotrexate · Chi-squared · p = <0.001
  • Group 1: Placebo + Methotrexate vs Group 4: Golimumab 100 mg + Methotrexate · Chi-squared · p = <0.001
  • Group 1: Placebo + Methotrexate vs Group 2: Golimumab 100 mg + Placebo · Chi-squared · p = 0.187
SecondaryChange From Baseline in Health Assessment Questionnaire (HAQ) Score at Week 14

The HAQ is 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0 (no difficulty), to 3 (inability to perform a task in that area). The average score across the functional areas yields an overall HAQ score which ranges from 0 (no disability) to 3 (completely disabled).

Time frame:
Baseline (Week 0) and Week 14
Reported as:
Median · Units on a scale
Change From Baseline in Health Assessment Questionnaire (HAQ) Score at Week 14
Units on a scaleGroup 1: Placebo + MethotrexateGroup 2: Golimumab 100 mg + PlaceboGroup 3: Golimumab 50 mg + MethotrexateGroup 4: Golimumab 100 mg + MethotrexateCombined Golimumab + Methotrexate
Change From Baseline in Health Assessment Questionnaire (HAQ) Score at Week 140.1250 (-0.1250 to 0.3750)0.2500 (-0.1250 to 0.6250)0.3750 (0.1250 to 0.7500)0.3750 (0.1250 to 0.6250)0.3750 (0.1250 to 0.7500)
Statistical analysis
  • Group 1: Placebo + Methotrexate vs Combined Golimumab + Methotrexate · ANOVA on van der Waerden noramal · p = <0.001
  • Group 1: Placebo + Methotrexate vs Group 3: Golimumab 50 mg + Methotrexate · ANOVA on van der Waerden normal scores · p = <0.001
  • Group 1: Placebo + Methotrexate vs Group 4: Golimumab 100 mg + Methotrexate · ANOVA on van der Waerden normal scores · p = <0.001
  • Group 1: Placebo + Methotrexate vs Group 2: Golimumab 100 mg + Placebo · ANOVA on van der Waerden normal scores · p = 0.097
SecondaryChange From Baseline in Total Van Der Heijde Modified Sharp (vdH-S) Score at Week 24

The vdH-S score is the sum of joint erosion score and joint-space narrowing (JSN) score. The total score ranges from 0 (best) to 448 (worst) with higher scores indicating more joint damage.

Time frame:
Baseline (Week 0) and Week 24
Reported as:
Median · Units on a scale
Change From Baseline in Total Van Der Heijde Modified Sharp (vdH-S) Score at Week 24
Units on a scaleGroup 1: Placebo + MethotrexateGroup 2: Golimumab 100 mg + PlaceboGroup 3: Golimumab 50 mg + MethotrexateGroup 4: Golimumab 100 mg + MethotrexateCombined Golimumab + Methotrexate
Change From Baseline in Total Van Der Heijde Modified Sharp (vdH-S) Score at Week 240.00 ± 2.3540.00 ± 1.5980.00 ± 2.7400.00 ± 1.3420.00 ± 2.159
Statistical analysis
  • Group 1: Placebo + Methotrexate vs Combined Golimumab + Methotrexate · ANOVA on van der Waerden normal · p = 0.551
  • Group 1: Placebo + Methotrexate vs Group 3: Golimumab 50 mg + Methotrexate · ANOVA on van der Waerden normal scores · p = 0.953
  • Group 1: Placebo + Methotrexate vs Group 4: Golimumab 100 mg + Methotrexate · ANOVA on van der waerden normal scores · p = 0.293
  • Group 1: Placebo + Methotrexate vs Group 2: Golimumab 100 mg + Placebo · ANOVA on van der Waerden normal scores · p = 0.361

Adverse events

Collected over Adverse event data were collected for 5 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1: Golimumab 50 mg SC Injections Only—33/105 (31.4%)96/105 (91.4%)
Group 2: Golimumab 100 mg SC Injections Only—84/184 (45.7%)160/184 (87%)
Group 3: Golimumab 50 and 100 mg SC Injections—55/145 (37.9%)118/145 (81.4%)
Most frequent serious events
Showing 10 of 189
Most frequent serious events
EventGroup 1: Golimumab 50 mg SC Injections OnlyGroup 2: Golimumab 100 mg SC Injections OnlyGroup 3: Golimumab 50 and 100 mg SC Injections
Rheumatoid ArthritisMusculoskeletal and connective tissue disorders2/1056/1845/145
CholelithiasisHepatobiliary disorders0/1055/1843/145
SepsisInfections and infestations1/1055/1841/145
CellulitisInfections and infestations1/1054/1841/145
Basal Cell CarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/1054/1841/145
OsteoarthritisMusculoskeletal and connective tissue disorders1/1053/1843/145
Uterine LeiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1050/1843/145
GoitreEndocrine disorders2/1050/1842/145
PneumoniaInfections and infestations2/1053/1842/145
Squamous Cell CarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/1052/1842/145
Most frequent other events
Showing 10 of 45
Most frequent other events
EventGroup 1: Golimumab 50 mg SC Injections OnlyGroup 2: Golimumab 100 mg SC Injections OnlyGroup 3: Golimumab 50 and 100 mg SC Injections
Upper Respiratory Tract InfectionInfections and infestations39/10564/18439/145
CoughRespiratory, thoracic and mediastinal disorders24/10535/18414/145
BronchitisInfections and infestations18/10527/18428/145
NasopharyngitisInfections and infestations15/10535/18424/145
PharyngitisInfections and infestations13/10520/18425/145
DiarrhoeaGastrointestinal disorders16/10524/18411/145
ArthralgiaMusculoskeletal and connective tissue disorders16/10518/18415/145
HypertensionVascular disorders8/10525/18421/145
Urinary Tract InfectionInfections and infestations9/10520/18420/145
Back PainMusculoskeletal and connective tissue disorders10/10522/18420/145

Baseline characteristics

Age, Continuous
Age, Continuous(years)Group 1: Placebo + MethotrexateGroup 2: Golimumab 100 mg + PlaceboGroup 3: Golimumab 50 mg + MethotrexateGroup 4: Golimumab 100 mg + MethotrexateTotal
Mean51.2 ± 11.9650 ± 11.4750.3 ± 10.9850 ± 10.7850.4 ± 11.36
Sex: Female, Male
Sex: Female, Male(Participants)Group 1: Placebo + MethotrexateGroup 2: Golimumab 100 mg + PlaceboGroup 3: Golimumab 50 mg + MethotrexateGroup 4: Golimumab 100 mg + MethotrexateTotal
Female1091057272358
Male2428171786
08

Study locations

52 sites
  • Mobile, Alabama, United States
  • Palo Alto, California, United States
  • Pasadena, California, United States
  • Upland, California, United States
  • Ormond Beach, Florida, United States
  • Palm Harbor, Florida, United States
  • Moline, Illinois, United States
  • Kansas City, Missouri, United States
  • Saint Louis, Missouri, United States
  • Lincoln, Nebraska, United States
  • Omaha, Nebraska, United States
  • Duncansville, Pennsylvania, United States
  • Richmond, Virginia, United States
  • Buenos Aires, Argentina
  • Cordoba, Argentina
  • Rosario, Argentina
  • S.M. De Tucuman, Argentina
  • San Miguel De Tucuman, Argentina
  • Clayton, Australia
  • Maroochydore, Australia
  • Melbourne, Australia
  • Victoria, British Columbia, Canada
  • St. John'S, Newfoundland and Labrador, Canada
  • Ottawa, Ontario, Canada
  • Toronto, Ontario, Canada
  • Sainte Foy, Quebec, Canada
  • Hamilton Ontario, Canada
  • Rancagua, Chile
  • Santiago De Chile, Chile
  • Santiago, Chile
  • Temuco Ix, Chile
  • Berlin, Germany
  • Hamburg, Germany
  • Hannover, Germany
  • Köln, Germany
  • Leipzig, Germany
  • Rostock, Germany
  • Budepest, Hungary
  • Anyang, Korea, Republic of
  • Daegu, Korea, Republic of
  • Pusan, Korea, Republic of
  • Seoul, Korea, Republic of
  • Monterrey, Mexico
  • Auckland, New Zealand
  • Rotorua, New Zealand
  • Timaru, New Zealand
  • Elblag, Poland
  • Kalisz, Poland
  • Szczecin, Poland
  • Warsaw, Poland
  • Warszawa N/A, Poland
  • Kaohsiung County, Taiwan
09

References and documents

Publications

  • Leu JH, Adedokun OJ, Gargano C, Hsia EC, Xu Z, Shankar G. Immunogenicity of golimumab and its clinical relevance in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Rheumatology (Oxford). 2019 Mar 1;58(3):441-446. doi: 10.1093/rheumatology/key309. PubMed 30412238 ↗
  • George MD, Ostergaard M, Conaghan PG, Emery P, Baker DG, Baker JF. Obesity and rates of clinical remission and low MRI inflammation in rheumatoid arthritis. Ann Rheum Dis. 2017 Oct;76(10):1743-1746. doi: 10.1136/annrheumdis-2017-211569. Epub 2017 Jun 12. PubMed 28606966 ↗
  • Kay J, Fleischmann R, Keystone E, Hsia EC, Hsu B, Zhou Y, Goldstein N, Braun J. Five-year Safety Data from 5 Clinical Trials of Subcutaneous Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis. J Rheumatol. 2016 Dec;43(12):2120-2130. doi: 10.3899/jrheum.160420. Epub 2016 Nov 1. PubMed 27803138 ↗
  • Mack ME, Hsia E, Aletaha D. Comparative Assessment of the Different American College of Rheumatology/European League Against Rheumatism Remission Definitions for Rheumatoid Arthritis for Their Use as Clinical Trial End Points. Arthritis Rheumatol. 2017 Mar;69(3):518-528. doi: 10.1002/art.39945. PubMed 27696724 ↗
  • Baker JF, Conaghan PG, Smolen JS, Aletaha D, Shults J, Emery P, Baker DG, Ostergaard M. Development and validation of modified disease activity scores in rheumatoid arthritis: superior correlation with magnetic resonance imaging-detected synovitis and radiographic progression. Arthritis Rheumatol. 2014 Apr;66(4):794-802. doi: 10.1002/art.38304. PubMed 24757132 ↗
  • Keystone EC, Genovese MC, Hall S, Miranda PC, Bae SC, Palmer W, Wu Z, Xu S, Hsia EC. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: results through 2 years of the GO-FORWARD study extension. J Rheumatol. 2013 Jul;40(7):1097-103. doi: 10.3899/jrheum.120584. Epub 2013 May 15. PubMed 23678153 ↗
  • Genovese MC, Han C, Keystone EC, Hsia EC, Buchanan J, Gathany T, Murphy FT, Wu Z, Parasuraman S, Rahman MU. Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study. J Rheumatol. 2012 Jun;39(6):1185-91. doi: 10.3899/jrheum.111195. Epub 2012 Apr 15. PubMed 22505702 ↗
  • Visvanathan S, Rahman MU, Keystone E, Genovese M, Klareskog L, Hsia E, Mack M, Buchanan J, Elashoff M, Wagner C. Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study. Arthritis Res Ther. 2010;12(6):R211. doi: 10.1186/ar3188. Epub 2010 Nov 17. PubMed 21083889 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2005, a primary completion of Sep 2007 and a completion of May 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2014, 6 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2005
First posted
Dec 13, 2005
Start
Dec 2005
Primary completionActual
Sep 2007
CompletionActual
May 2012
Results first posted
Mar 21, 2014
Last update
Apr 29, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00264550
Lead sponsor
Centocor, Inc.
Collaborators
Schering-Plough
Responsible party
Sponsor
First posted
Dec 13, 2005
Start date
Dec 2005
Primary completion
Sep 2007
Completion
May 2012
Results posted
Mar 21, 2014
Last update
Apr 29, 2014

Study contacts

Centocor, Inc. Clinical Trial
study director · Centocor, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Golimumab · Methotrexate

Start the discussion